We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

PCSK9

PCSK9 inhibitors and degraders target a secreted protein that limits cholesterol uptake by the liver. Proprotein convertase subtilisin/kexin type 9 (PCSK9) was described in 2003 as neural apoptosis-regulated convertase 1 (NARC-1), a convertase expressed in liver and brain. In the same year, mutations in its gene were linked to autosomal dominant hypercholesterolemia. Secreted PCSK9 binds low-density lipoprotein (LDL) receptors and routes them to lysosomal degradation. SBC-115076 and laroprovstat are small-molecule PCSK9 inhibitors, while PF-06446846 hydrochloride selectively stalls ribosomes during PCSK9 translation. Inclisiran is a small interfering RNA (siRNA), and PCSK9 autophagic degrader 2 removes the protein through autophagy.

1 Item

  • PCSK9 ligand 1
    Cat. No.
    A77046
    CAS No.
    2215931-60-3

    PCSK9 ligand 1

    PCSK9 ligand 1 is a selective ligand for proprotein convertase subtilisin/kexin type 9 (PCSK9), which plays a critical role in cholesterol metabolism and regulation. This compound does not interfere with the functional activity of PCSK9, making it a valuable tool for studying PCSK9 interactions and cholesterol homeostasis. It is applicable in research focused on lipid metabolism, cardiovascular diseases, and potential therapeutic interventions targeting PCSK9 pathways.

    In stock View Details
    5 mg
    $1,680.00
    All 1 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...